Osteopathy
What studies of osteopathy found
At a glance, by condition
Long COVID: C Might help, very uncertain
Based on the strongest evidence, studies with no comparison group (very low certainty), for pain.
1 outcome rated · see each below
How we got this
Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.
What this means: Osteopathy might help some people with long COVID, but research can’t show it yet. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.
Ask about this treatment
The grades, in plain words
Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.
- AHelpsImprovement, high certaintyProbably helpsImprovement, moderate certainty
- BMay helpImprovement, low certainty
- Osteopathy · Long COVID is hereCMight help, very uncertainImprovement, very low certaintyMixed resultsStudies disagree
- DLittle or no differenceStudies found little or no difference
- FHarmsIt made things worse
By symptom and daily life
Long COVID
Pain2 studies · 1 (few people) person took part in osteopathy Improvement C
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all); not all results were tested against chance.
Studies with no comparison group2 studies · 1 person with results (few people)
Pain improved.
The evidence is very uncertain about the effect of osteopathy on pain in long COVID. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people (1 in all)
- Not all results were tested against chance
See the 2 studies
-
Corona With Lyme: A Long COVID Case Study. (2023)
- People in the study
- 1 in the study
- Dose
- —
- Outcome
- severity and frequency of associated myalgias, headaches, and scalp allodynia
- Effect
- better (not tested)
- Risk of bias
- case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
-
Osteopathic manipulative treatment for pediatric Long-COVID headache: A case report (2023)
- People in the study
- —
- Dose
- —
- Outcome
- long-COVID headache
- Effect
- better (not tested)
- Risk of bias
- case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Side effects
Side effects studies reported4 kinds
| Side effect | Studies that reported it |
|---|---|
| Anxiety or irritability | 1 study |
| Fatigue | 1 study |
| Headache | 1 study |
| Worse symptoms or a flare | 1 study |
All papers
- Acute Effects of Osteopathic Treatment in Long COVID-19 Patients with Fatigue Symptoms: A Randomized, Controlled Trial.2025 · placebo trial · 42 randomised
Summary
This single-blind, randomized, controlled trial asked whether a single osteopathic treatment changes heart rate variability in long COVID with persistent fatigue. It included 42 participants at a rehabilitation clinic in Germany, with recruitment and data collection between June and November 2023; 21 were allocated to a 45 min standardized osteopathic treatment and 21 to a 45 min sham treatment. Heart rate variability was recorded from a 10 min resting electrocardiogram at baseline (T1), immediately after the intervention (T2), and 48 h later (T3). In the osteopathy arm, RMSSD increased from t1 (mean: 17.8 ms ± 11.2, n = 15) to t2 (mean: 21.6 ms ± 9.3; g = 0.82, 95% CI [0.19, 1.40]); the stress index decreased from t1 (mean: 16.2 ± 6.2, n = 18) to t2 (mean: 12.8 ± 5.0; g = −1.02, 95% CI [−1.33, −0.59]); SDNN increased from t1 (mean: 19.6 ms ± 8.6, n = 17) to t2 (mean: 26.0 ms ± 12.5; g = 0.80, 95% CI [0.38, 1.18]); mean RR intervals increased from t1 (mean: 869 ms ± 104, n = 19) to t2 (mean: 934 ms ± 102; g = 1.01, 95% CI [0.43, 1.61]); mean HR decreased from t1 (mean: 67.3 bpm ± 7.8, n = 18) to t2 (mean: 62.3 bpm ± 5.9; g = −1.10, 95% CI [−1.62, −0.48]); LF increased from t1 (mean: 206 ms2 ± 153, n = 17) to t2 (mean: 329 ms2 ± 277; g = 0.53, 95% CI [0.07, 0.86]); HF rose from t1 (mean: 146 ms2 ± 207, n = 14) to t2 (mean: 213 ms2 ± 202; g = 0.48, 95% CI [−0.14, 0.99]); total power rose from t1 (mean: 487 ms2 ± 457, n = 18) to t2 (mean: 822 ms2 ± 773; g = 0.62, 95% CI [0.35, 0.89]). The LF/HF ratio remained statistically unchanged across all time points within the osteopathy group. Significant between-group differences were observed for mean heart rate and mean of RR intervals (p < 0.05). Side effects and withdrawals were not reported. The paper also states self-reported fatigue severity was reduced.
- Can osteopathy reduce symptoms of chronic fatigue syndrome?1999 · compared with another group
Summary
The objective was to evaluate the efficacy of a manual treatment protocol for CFS/ME. 9 patients suffering from CFS/ME received the protocol. They were compared with 9 age and gender-matched CFS/ME sufferers who were allowed to choose any treatment other than manual therapy and with 9 age and gender-matched healthy volunteers. All were assessed at 0 and 12 months; treatment duration is not reported. Assessments included isometric testing and EMG of the knee extensor muscles alongside the Profile of Fatigue Related States questionnaire. Significant increases in peak and impulse torque were found and corresponded to improvements in the Profile of Fatigue Related States questionnaire in the treatment group only; no other significant changes were found. The abstract does not report side effects or withdrawals. The authors conclude that post-exercise muscle function in CFS/ME is improved following specialised osteopathic intervention. They also suggest reduction of lymphatic drainage as a possible aetiological factor in the observed muscle fatigue. The abstract does not state limitations.
- An evaluation of the effectiveness of osteopathic treatment on symptoms associated with myalgic encephalomyelitis. A preliminary report.1998 · compared with another group · 80 in the study · 58 started
Summary
This preliminary report evaluated osteopathic treatment for symptoms associated with ME/CFS. Initially 80 patients volunteered; the study assessed 58 people with confirmed ME, divided into a patient group of 34 and a control group of 24. Patient-group participants were referred to one author's clinical practice; control participants came from Action for ME. The patient group received osteopathic treatment for 12 months, including soft tissue massage, spinal manipulation and articulation, functional and cranio-sacral techniques, lymphatic drainage, thoracic mobility exercises, contrast bathing, advice to reduce activity to half capability and then gradually increase walking and back-stroke swimming. The control group received no manual therapy but could receive other treatments. Outcomes included self-report questionnaires and knee-extensor fatigue testing. The mean questionnaire score improved by 40% in the patient group versus a 1% worsening in the control group (p less than 0.000.5). All patient-group subjects had a reduction in total score, while for nearly 50% of the control group the score was greater at the end. Effective work done rose from 1791 Nms to 2259 Nms (p less than 0.0005). Patient-group depression was slightly worse after six months than at three months; anxiety and sleep disturbance rose slightly in the second quarter. Forty patients were initially chosen for the patient group; five were disqualified, one left the country and one dropped out, leaving 33. Control numbers dwindled from 40 to 23.
- The involvement of cerebrospinal fluid and lymphatic drainage in chronic fatigue syndrome (CFS/ME)2005 · no comparison group
Summary
This thesis tested a new hands-on osteopathic treatment, developed by the author, in people with CFS/ME, in two clinical trials. The first looked at symptom change after a year of treatment with questionnaires and at leg muscle strength tests. The second repeated the questionnaires, used brain scans and lymph scans, and repeated the muscle tests with better equipment. The abstract says the treatment was statistically validated in both phases but gives no numbers, group sizes or comparison group, so no result is recorded. Side effects are not mentioned.
- Long-COVID symptoms improved after MDMA and psilocybin therapy: A case report.2024 · case report
Summary
This case report describes a 41-year-old female with Long-COVID syndrome after contracting COVID-19 in February 2022. She self-medicated with psilocybin and MDMA under a therapist-recommended protocol. The first dosing session, on May 05, 2022, was 1 g of dried golden teacher psilocybin cubensis mushrooms; she reported a 20% improvement in depression, fatigue, joint pains, and headache for 7 days. The second session, 24 days later, was MDMA 125 mg followed 1 h later by 2 g of mushrooms in tea and 1 h later by a second 2 g of mushrooms in tea. After this session the patient reported significant improvement in post-COVID symptoms; headache frequency reduced to approximately once per week from a May 2022 baseline of 5 per week, duration decreased to less than 2–4 h per attack from a typical 8–12 h, and she rated symptom improvement approximately 80%. After another 2 g dose, symptoms abated to 90% relief. She later had an early November relapse, then after 2 g on November 24th reported complete resolution and returned to work 3 days later. Harms included chills and shivering with a sensation of being cold while “coming up” and transient nausea and emesis 40 min after ingestion. No comparison group was studied.
- Corona With Lyme: A Long COVID Case Study.2023 · case report · 1 in the study
Summary
This case report describes a previously healthy 26-year-old female medical student living in New York, NY, who developed long COVID after a presumed acute SARS-CoV-2 infection in March 2020, with a concurrent perceived early-disseminated Lyme disease infection. The three-year arc covers numerous trial-and-error treatments: a two-week regimen of doxycycline 100 mg twice a day, metformin escalation alongside diet modifications, graded compression stockings, breathing exercises, increases in caffeine and salt consumption with increased fluid intake, a horizontal cardio exercise program with rest periods, osteopathic manipulative treatment, cognitive behavioral therapy, sleep hygiene improvements, supplements (vitamin C, vitamin D, vitamin B12, B-complex, n-acetyl cysteine, turmeric extract), a two-dose Moderna mRNA COVID-19 vaccination course, and abortive headache therapies (Excedrin or Fioricet and prochlorperazine). The authors report a moderate reduction in cycle length and morning hypoglycemic symptoms with metformin, a moderate reduction in myalgias, headaches and scalp allodynia with osteopathic manipulative treatment, some relief of post-COVID headache, help with headache pain, orthostatic palpitations, fatigue and brain fog from abortive therapies plus caffeine, salt and fluid intake, moderate improvements in fatigue and brain fog in the first 24 hours after the first vaccine dose, moderate symptom alleviation from digital interventions, and small but recognizable differences in fatigue and cognition from sleep hygiene. No improvement in symptoms other than mild reduction in right shoulder pain followed the doxycycline regimen. Supplements provided no discernable benefit. The patient reports full recovery from long COVID with residual blurred vision and oligomenorrhea. Reported harms include worsening blurred vision, palpitations, heat intolerance and near-syncopal events; a moderate increase in fatigue and brain fog with a CGRP antagonist; fatigue exacerbation with traditional exercise rehabilitation; symptom re-exacerbations with compression stockings; and increased headache frequency and duration with n-acetyl cysteine. The abstract describes near-total remission.
- Osteopathic manipulative treatment for pediatric Long-COVID headache: A case report2023 · case report
Summary
This case report from the United States describes one child who had a headache for 12 months after a COVID infection, diagnosed as long-COVID headache. An osteopathic examination of the head found what the authors call a high burden of somatic dysfunction, meaning areas of restricted movement felt by hand. The child was treated with osteopathic manipulative treatment (OMT), a hands-on treatment in which an osteopathic doctor moves and presses the muscles, joints and skull, given as part of an individual treatment plan. The authors report that the headache went away after the treatment, and they write that OMT may have been the reason, without being certain. The text available here gives no details of how many sessions were given, over what period, how the headache was measured, or how long the child was followed afterwards. It reports no side effects. Because this is a single case with no comparison, it cannot show whether the headache would have eased on its own. The authors call for further research and clinical trials of OMT in children with long COVID.
- Successful outcome of musculoskeletal injury leads to a reduction in chronic fatigue: A case report.2018 · combination: given with other treatments · 1 in the study
Summary
This case report describes one 19-year-old male student, referred privately, with a two-year history of left-sided shoulder girdle pain (VAS 8/10) and a diagnosis of chronic fatigue syndrome. He was treated with osteopathic manipulative treatment (OMT) over four clinical visits across a four-month period, combined with corrective exercise and orthotics. There was no comparison group. The authors report that over the course of four treatments pain level reduced from 8/10 to 0/10, strength testing increased from 4/5 to 5/5, and GHJ testing improved (5/5). By the fourth visit the patient reported participation in a cricket match and had experienced no reaction in shoulder symptoms or increase in CFS levels. The patient also reported that, in their opinion, due to a reduction in pain, their CFS might have improved. The authors note limitations including a lack of quantitative and qualitative outcome measures, the retrospective collection of information, and the possibility that the patient might have recovered naturally without osteopathic intervention. They also state that fatigue was never actually measured and that the present study cannot state that specific shoulder exercises were any better compared to general gym sessions for the management of CFS.
- A mixed-methods systematic review of post-viral fatigue interventions: Are there lessons for long Covid?2021 · systematic review
Summary
This mixed-methods systematic review asked whether post-viral fatigue interventions offer lessons for long Covid. Online databases were searched in October 2020, and 40 papers were selected. The included fatigue interventions involved 25 studies in CFS/ME, nine in fibromyalgia and eight in unexplained fatigue. Treatments varied widely and were compared with controls, typically usual care or waiting lists; fatigue severity was the main outcome. Intervention duration varied and is not quantified in the recorded data. The review reported mean differences for several interventions. The largest mean difference was for the Three Principles/Innate Health programme (MD -39.0, 95% CI -51.8 to -26.2, SMD = 1.670). Group-based CBT also showed reductions (MD -27.5, 95% CI -33.7 to -21.3, SMD = 1.170; MD -23.7, 95% CI -29.2 to -18.2, SMD = 2.266). Smaller mean differences were reported for GET (MD -11.5, 95% CI -17.6 to -5.4, SMD = 0.524) and self-regulation based physical activity (MD -9.9, 95% CI -16.3 to -3.4, SMD = 0.513). TENS (MD -6.0, 95% CI -16.9 to 4.9, SMD = 0.239), Tai Ji Quan (MD -0.4, 95% CI -9.6 to 8.9, SMD = 0.023) and supportive listening (MD 1.06, 95% CI -1.4 to 3.6, SMD = -0.111) showed little or no benefit. Doxycycline mean differences were positive (MD 6.3, 95% CI 3.7 to 8.8, SMD = -0.752; MD 8.75, 95% CI 6.36 to 11.14, SMD = -1.120). No side effects, withdrawals or worsening were reported in the recorded data.
- Alternative medical interventions used in the treatment and management of myalgic encephalomyelitis/chronic fatigue syndrome and fibromyalgia.2010 · systematic review
Summary
The review included 70 controlled clinical trials of alternative and complementary treatments and nonpharmacological supplements for ME/CFS and fibromyalgia; searches ran up to April 2007. It did not have its own treatment arm or comparison group; it summarized trials with control or comparison conditions. The review did not report one treatment dose or duration. Outcomes in included trials covered laboratory tests, physical functioning, psychologic functioning, and quality of life. The review reports that some trials showed at least one positive effect and some showed null or ambiguous results; it states that no firm conclusions can be made. Only three studies (4%) reported adverse side-effects such as bruising and rashes. For acupuncture, three RCTs reported dropout rates of around 15%–35% in all intervention groups. The authors state publication bias: beneficial effects tend to be published while negative results may remain unpublished. They also state the methodological quality of reporting was generally poor and that no definite CAM treatment recommendations can be made for ME/CFS or FM.
- Interventions for the treatment, management and rehabilitation of patients with chronic fatigue syndrome/myalgic encephalomyelitis: an updated systematic review.2006 · systematic review
Summary
This updated systematic review asked whether any intervention is effective for treatment, management or rehabilitation of adults and children with CFS/ME. The authors searched eleven electronic databases and included 70 studies, of which 59 were RCTs; comparisons were between treatment and control groups. Interventions included CBT, GET, rehabilitation, immunological and pharmacological treatments, supplements and complementary therapies. Outcomes covered physical, psychological, laboratory/physiological and quality-of-life measures. CBT and GET appeared to reduce symptoms and improve function based on RCTs. In a CBT trial (n=69), physical functioning, fatigue and symptoms favoured CBT (P<0.003) and school attendance favoured treatment (P=0.04). Another CBT trial (n=65) found no significant difference for fatigue, anxiety and depression, or disability. In GET trials, CGI and fatigue favoured treatment (n=49; P<0.03), and fatigue and depression/anxiety were significantly better (n=61; P=0.027). One GET trial reported withdrawal of one patient in each group because of worsening symptoms; eleven patients withdrew because of adverse events in a GET with or without fluoxetine trial. Galantamine (n=434) showed no significant differences; 130 patients withdrew, 389 reported adverse events and 88 withdrew. Acetyl-L-carnitine and propionyl-L-carnitine (n=90) improved general fatigue in PLC (P=0.004) and combined group (P<0.001), and mental fatigue in ALC group (P=0.015); 8 patients withdrew due to side effects. Staphylococcus toxoid (n=98) had 13 treatment-group and 7 placebo-group patients with side effects. Hydrocortisone/fludrocortisone (n=80) found no significant differences.
- Interventions for the treatment and management of chronic fatigue syndrome: a systematic review.2001 · systematic review
Summary
This systematic review asked whether interventions for chronic fatigue syndrome (CFS) work. Nineteen specialist databases were searched, and 44 trials met inclusion criteria: 36 randomized controlled trials and 8 controlled trials. Treatments were grouped by type and compared with control conditions. Outcomes were classified as positive, negative, or no effect. Three randomized controlled trials of GET all showed an overall beneficial effect compared with control groups. Three of four randomized controlled trials of CBT found a positive overall effect; one controlled trial did not find overall beneficial effects. One randomized controlled trial found no effect of fluoxetine either alone or with GET. Hydrocortisone showed an overall beneficial effect in one randomized controlled trial and some beneficial effects in another. For immunoglobulin, two randomized controlled trials showed an overall beneficial effect, two showed some positive effects, and the largest reported no effect. Acyclovir showed a negative effect for one outcome. Randomized controlled trials of fludrocortisone, antidepressants, moclobemide, sulbutiamine, growth hormone and galanthamine hydrobromide found no effects. Oral NADH showed an overall beneficial effect in one randomized controlled trial. Harms included withdrawals from immunoglobulin therapy (2 due to severe constitutional symptoms, 1 due to a skin eruption, 1 due to mild but transient liver failure, 1 due to phlebitis, and 2 whose adverse effects were not reported), 3 withdrawals from acyclovir due to reversible renal failure, and 2 participants leaving the magnesium group after a generalized rash. CBT trials had a dropout rate of 19% (114/589), GET trials 18% (68/370), and pharmacological trials 11% (99/869).